To amend the Federal Food, Drug, and Cosmetic Act and the Defense Production Act of 1950 to prohibit the Federal Government from limiting State access to key therapies, such as monoclonal antibodies, and from prioritizing Federal contracts over State contracts relating to purchasing supplies to combat the COVID-19 pandemic.

Summary

This bill restricts various presidential and federal authorities related to the acquisition of supplies to combat COVID-19. Specifically, the bill prohibits the President from exercising certain authorities under the Defense Production Act of 1950 to prioritize the performance of federal contracts or orders for COVID-19 supplies over the performance of state or territorial contracts or orders. In addition, states or territories may use federal COVID-19 relief funds for COVID-19 supplies that they had been unable to purchase because of prioritized performance of federal contracts or orders. (The Defense Production Act of 1950 confers upon the President a broad set of authorities to influence domestic industry in order to provide essential materials and goods needed for the national defense.) Additionally, the Food and Drug Administration may not ration, limit, restrict access to, or otherwise control the quantity of a medical product authorized for use during an emergency, including by requiring products to be distributed through a state- or territorial-based system.

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

1. 25 February 2022

   Introduced

   Referred to the Committee on Energy and Commerce, and in addition to the Committee on Financial Services, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

   Source: IntroReferral

2. 25 February 2022

   Introduced

   Introduced in House

   Source: IntroReferral

3. 25 February 2022

   Introduced

   Introduced in House

   Source: IntroReferral

4. 28 February 2022

   Referred

   Referred to the Subcommittee on Health.

   Source: Committee

Votes

No vote records are attached yet.

Versions

• Introduced in House · 25 February 2022 · Official file

Documents

3 official files

• Introduced in House (text)

  Introduced in House · EN · 25 February 2022

  ViewDownloadOpen at official source

• Introduced in House (PDF)

  Introduced in House · EN · 25 February 2022

  ViewDownloadOpen at official source

• Introduced in House

  summary · EN · 25 February 2022

  Open at official source

Sponsors

• Rep. Cloud, Michael [R-TX-27] · R · Sponsor
• Daniel Webster · R · Sponsor
• Andy Biggs · R · Sponsor
• Mary Miller · R · Sponsor
• Thomas Tiffany · R · Sponsor
• Byron Donalds · R · Sponsor
• Mo Brooks · R · Cosponsor
• · hsif00 · Standing
• · hsba00 · Standing

Related records

• related to → A bill to amend the Federal Food, Drug, and Cosmetic Act and the Defense Production Act of 1950 to prohibit the Federal Government from limiting State access to key therapies, such as monoclonal antibodies, and from prioritizing Federal contracts over State contracts relating to purchasing supplies to combat the COVID-19 pandemic.